Baltimore, MD – According to filings with the U.S. Securities and Exchange Commission, Delfi Diagnostics is raising $224,999,876.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Victor Velculescu played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Delfi Diagnostics
Delfi uses novel machine learning algorithms to analyze fragments of cell-free DNA, resulting in the accurate detection of cancer from a single blood sample. Existing screening methods and tests depend on detecting known cancer-associated mutations and alterations. Learn how Delfis scalable approach quickly scans millions more data points to detect previously unrecognized cancer-associated cell-free DNA fragments. Delfis team includes leading experts in cancer biology, bioinformatics, machine learning, and public health.

To learn more about Delfi Diagnostics, visit http://delfidiagnostics.com/

Contact:
Victor Velculescu, President and Chief Executive Officer
410-961-9015
velculescu@delfidiagnostics.com
https://www.linkedin.com/in/victor-velculescu-md-phd-1241716/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved